Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully issued and paid-up
11 April 2024 - 3:00AM
Oxurion Receives EUR 450,000 in the framework of the Atlas Funding
Program : Eleventh tranche fully issued and paid-up
Oxurion Receives EUR 450,000 in the
framework of the Atlas Funding ProgramEleventh
tranche fully issued and paid-up
Leuven, BELGIUM, 10 April 2024 – 07.00
PM CET – Oxurion NV (Euronext Brussels: OXUR), a
biopharmaceutical company based in Leuven, today communicates it
has received an aggregate amount of EUR 450,000 in the framework of
the Atlas Funding Program.
On April 10, 2024, the Company issued the
Eleventh Tranche consisting of 18 convertible bonds, for an
aggregate amount of EUR 450,000.
This tranche has been issued in accordance with
the agreement reached with Atlas end of 2023, as further described
in the press release issued by the Company on December 28,
2023.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is engaged in
developing next-generation standard of care ophthalmic therapies
for the treatment of retinal disease. Oxurion is based in Leuven,
Belgium. More information is available at www.oxurion.com.
Please contact for additional information:
|
Oxurion NVPascal GhosonChief Executive
Officerpascal.ghoson@oxurion.com |
Backstage CommunicationJurgen
VluijmansPartnerjurgen@backstagecom.be |
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From Dec 2024 to Jan 2025
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From Jan 2024 to Jan 2025
